Literature DB >> 6618435

Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis.

J E Hegarty, K T Nouri Aria, B Portmann, A L Eddleston, R Williams.   

Abstract

A prospective study was performed to evaluate the outcome of treatment withdrawal in 30 patients with "autoimmune" chronic active hepatitis in remission for periods of 1.5 to 9 years on maintenance corticosteroid and azathioprine therapy. Reactivation of disease, with marked rises in serum aminotransferase level (mean 668 +/- S.D. 458 IU per liter) and accompanied by severe symptoms, occurred in 25 (87%) patients within 52 weeks (median 9 weeks; range 5 to 52) and was associated with the histological features of piecemeal necrosis and lobular hepatitis in all 20 liver biopsies examined. Age, sex, duration of disease and remission, presence of cirrhosis, autoantibody status, or immunoglobulin levels did not differentiate patients who relapsed from those who remained in remission. The response to reinstitution of treatment with prednisolone was satisfactory in 25 patients and clinical and biochemical abnormalities resolved within 10 weeks (median 6; range 3 to 10), death occurred in one patient within 48 hr of readmission to hospital.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6618435     DOI: 10.1002/hep.1840030510

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  45 in total

1.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.

Authors:  J Devlin; J O'Grady
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

Review 2.  Autoimmune hepatitis.

Authors:  E A Roberts
Journal:  Indian J Pediatr       Date:  1995 Sep-Oct       Impact factor: 1.967

3.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

Review 4.  Immunological aspects of liver disease.

Authors:  A L Eddleston; P T Donaldson; J E Hegarty; B D Reed
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 5.  Chronic active hepatitis.

Authors:  P J Johnson; I G McFarlane
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 6.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

7.  Exacerbated autoimmune hepatitis successfully treated with leukocytapheresis and bilirubin adsorption therapy.

Authors:  K Sawada; K Ohnishi; T Kosaka; S Chikano; A Egashira; M Okui; S Shintani; M Wada; K Nakasho; T Shimoyama
Journal:  J Gastroenterol       Date:  1997-10       Impact factor: 7.527

8.  Treatment of autoimmune hepatitis.

Authors:  P J Johnson
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

9.  Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

Review 10.  Hepatic disorders. Features and appropriate management.

Authors:  M A Aldersley; J G O'Grady
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.